干扰素联合胸腺肽α_1治疗免疫耐受期乙肝病毒携带者的疗效观察

目的:评价干扰素联合胸腺肽α1治疗免疫耐受期乙肝病毒携带者的疗效性和安全性,探讨两者联合治疗的协同作用。方法:97例患者随机分成两组,治疗组47例患者均给予干扰素联合胸腺肽α1治疗;对照组50例患者除不用胸腺肽α1外,干扰素的治疗方法及疗程相同。结果:两药联用使治疗组在疗程结束时及疗程结束后6个月HBeAg血清转换率、HBV-DNA转阴率均显著高于对照组,治疗组和对照组T细胞亚群CD4+以及CD4+/CD8+在治疗后均显著升高(P<0.05),但治疗后治疗组和对照组之间没有显著差异。结论:两药联用使HBV-DNA阴转率及HBeAg血清转换率近、远期疗效均明显优于对照组,它能使部分患者转氨酶升高而脱离免疫耐受,还可通过自身免疫清除体内的乙肝病毒,可见,对处于免疫耐受的乙肝病毒携带者不失为一种较有效而安全的治疗方法,由于本研究观察例数有限,尚需进一步观察验证。

Interferon alpha with thymopeptide alpha1 in the treatment of immune tolerance to hepatitis B vivus carrier

Objective To study the efficiency and safety of combination therapy with interferon alpha and thymopeptide alpha1 in the immune tolerance HBV carriers. Method 97 patients were randomly divided into two groups, therapy group and control group. The patients in both groups received IFN-α and the patients in therapy group received coincidentally thymopeptide α1. Results At the end of treatment and 6 months later, both HBeAg seroconversion and HBV-DNA in therapy group are significantly higher than those in control group (P<0.05). The expression of CD4+ and value of CD4+/CD8+ on T cells in the two groups are both higher than those before treatments (P<0.05,t-test), while there is no significant difference between the two groups after treatments. Conclusion Interferon combined with thymopeptide alpha1 can effectively break the state of immune-tolerance of HBV carriers and recover the normal immunocompetence of host to HBV. It's applicable to view that combination therapy with Interferon and thymopeptide alpha1 in patients in immune-tolerance with on HBV is a sort of relatively effective and safe therapy method.